Vestar Inc. (NASDAQ:VSTR) announced Thursday that FDA hasgranted orphan drug designation to DaunoXome, the company'sliposomal formulation of the anti-cancer agent daunorubicin,for treating advanced HIV-associated Kaposi's sarcoma.

Vestar of San Dimas, Calif., submitted to FDA a new drugapplication (NDA) on DaunoXome for this indication inFebruary.

(c) 1997 American Health Consultants. All rights reserved.